We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Y-mAbs Therapeutics, Inc. (YMAB - Free Report) shares ended the last trading session 103.3% higher at $8.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.7% loss over the past four weeks.
The stock rallied after SERB Pharmaceuticals announced that it would acquire Y-mAbs Therapeutics in an all-cash transaction for an equity value of approximately $412 million. The transaction is expected to be closed by the fourth quarter of 2025.
This company is expected to post quarterly loss of $0.27 per share in its upcoming report, which represents a year-over-year change of -28.6%. Revenues are expected to be $18.43 million, down 19.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For YmAbs Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on YMAB going forward to see if this recent jump can turn into more strength down the road.
YmAbs Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Oculis Holding AG (OCS - Free Report) , another stock in the same industry, closed the last trading session 0.6% lower at $17.84. OCS has returned -4.3% in the past month.
For Oculis Holding AG, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.53. This represents a change of +5.4% from what the company reported a year ago. Oculis Holding AG currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
Y-mAbs Therapeutics, Inc. (YMAB - Free Report) shares ended the last trading session 103.3% higher at $8.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.7% loss over the past four weeks.
The stock rallied after SERB Pharmaceuticals announced that it would acquire Y-mAbs Therapeutics in an all-cash transaction for an equity value of approximately $412 million. The transaction is expected to be closed by the fourth quarter of 2025.
This company is expected to post quarterly loss of $0.27 per share in its upcoming report, which represents a year-over-year change of -28.6%. Revenues are expected to be $18.43 million, down 19.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For YmAbs Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on YMAB going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
YmAbs Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Oculis Holding AG (OCS - Free Report) , another stock in the same industry, closed the last trading session 0.6% lower at $17.84. OCS has returned -4.3% in the past month.
For Oculis Holding AG, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.53. This represents a change of +5.4% from what the company reported a year ago. Oculis Holding AG currently has a Zacks Rank of #3 (Hold).